US2006188880A1PendingUtilityA1

Method for detecting an analyte in a sample

40
Assignee: HINNAH SILKEPriority: Dec 20, 2002Filed: Dec 19, 2003Published: Aug 24, 2006
Est. expiryDec 20, 2022(expired)· nominal 20-yr term from priority
Inventors:Silke Hinnah
C12Q 1/6837G01N 33/54306C12Q 1/68C12Q 1/6818
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for detecting an analyte in a sample comprising the steps of providing detection probes being labeled with a first reporter, which detection probes are capable of binding to the analyte, providing a solid support, providing capture probes being bound or capable of binding to the solid support, which capture probes are capable of binding to the analyte, thus concentrating the analyte on the solid support, contacting the sample with the detection probes, the solid support and the capture probes, and detecting the detection probes, wherein the detection of detection probes is conducted in the presence of quenching probes binding to surplus detection probes not being bound to the analyte and thereby quenching at least partially an emission of the first reporter of said surplus detection probes and/or the solid support is labeled with a second reporter different from the first reporter, imaging the sample at an emission wavelength of the second reporter, generating a mask obtained from imaging the sample at the emission wavelength of the second reporter and applying this mask to an image of the sample used for detecting the detection probes.

Claims

exact text as granted — not AI-modified
1 . A method for detecting an analyte in a sample comprising the steps of 
 providing detection probes being labeled with a first reporter, which detection probes are capable of binding to the analyte,    providing a solid support,    providing capture probes being bound or capable of binding to the solid support, which capture probes are capable of binding to the analyte, thus concentrating the analyte on the solid support,    contacting the sample with the detection probes, the solid support and the capture probes, and    detecting the detection probes, wherein    the detection of detection probes is conducted in the presence of quenching probes binding to surplus detection probes not being bound to the analyte and thereby quenching at least partially an emission of the first reporter of said surplus detection probes and/or    the solid support is labeled with a second reporter different from the first reporter, imaging the sample at an emission wavelength of the second reporter, generating a mask obtained from imaging the sample at the emission wavelength of the second reporter and applying this mask to an image of the sample used for detecting the detection probes.    
     
     
         2 . A method for detecting an analyte in a sample comprising the steps of 
 providing detection oligonucleotides being labeled with a first reporter, which detection oligonucleotides are capable of binding to the analyte,    providing a solid support,    providing capture oligonucleotides being bound or capable of binding to the solid support, which capture oligonucleotides are capable of binding to the analyte, thus concentrating the analyte on the solid support,    contacting the sample with the detection oligonucleotides, the solid support and the capture oligonucleotides, and    detecting the detection oligonucleotides, wherein    the detection of detection oligonucleotides is conducted in the presence of quenching oligonucleotides hybridizing to surplus detection oligonucleotides not being bound to the analyte and thereby quenching at least partially an emission of the first reporter of said surplus detection oligonucleotides and/or    the solid support is labeled with a second reporter different from the first reporter, imaging the sample at an emission wavelength of the second reporter, generating a mask obtained from imaging the sample at the emission wavelength of the second reporter and applying this mask to an image of the sample used for detecting the detection oligonucleotides.    
     
     
         3 . The method according to  claim 1  being conducted in a homogeneous format.  
     
     
         4 . The method according to  claim 1  wherein the first and/or second reporter is luminescent, in particular fluorescent.  
     
     
         5 . The method according to  claim 1  wherein the first and/or second reporter is a dye.  
     
     
         6 . The method according to  claim 1  wherein the detection probes, in particular the detection oligonucleotides, are labeled with a first fluorescent dye and/or the solid support is labeled with a second fluorescent dye.  
     
     
         7 . The method according to  claim 2  wherein a hybrid between detection oligonucleotides and analyte has a higher melting temperature than a hybrid between detection oligonucleotides and quenching oligonucleotides.  
     
     
         8 . The method according to  claim 7  wherein a melting temperature of a hybrid between detection oligonucleotides and analyte is at least 1° C., more preferably at least 2° C., even more preferably at least 5° C. and most preferably at least 10° C. higher than a melting temperature of a hybrid between detection oligonucleotides and quenching oligonucleotides under test conditions.  
     
     
         9 . The method according to  claim 2  wherein contacting the sample with the detection oligonucleotides is performed under first hybridization conditions allowing the generation of a stable hybrid between detection oligonucleotides and analyte.  
     
     
         10 . The method according to  claim 2  wherein contacting the sample with the quenching oligonucleotides is performed under second hybridization conditions allowing the generation of a stable hybrid between surplus detection oligonucleotides not being bound to the analyte and quenching oligonucleotides.  
     
     
         11 . The method according to  claim 10  wherein said second hybridization conditions do not destabilize a hybrid between detection oligonucleotides and analyte formed under said first hybridization conditions.  
     
     
         12 . The method according to  claim 1  wherein the capture probes, in particular the capture oligonucleotides, are covalently bound to the solid support.  
     
     
         13 . The method according to  claim 1  wherein the capture probes, in particular the capture oligonucleotides, are capable of binding to the solid support via affinity interaction.  
     
     
         14 . The method according to  claim 13  wherein the capture probes/capture oligonucleotides comprise a first affinity unit capable of binding to a second affinity unit attached to the solid support.  
     
     
         15 . The method according to  claim 14  wherein the first affinity unit is biotin and the second affinity unit is streptavidin or avidin.  
     
     
         16 . The method according to  claim 1  wherein the solid support is a bead, a cell, a pollen, or a plurality thereof.  
     
     
         17 . The method according to  claim 1  wherein the first reporter labeling the detection probes/detection oligonucleotides differs in its excitation wavelength and/or its emission wavelength from the second reporter labeling the solid support.  
     
     
         18 . The method according to  claim 17  wherein the difference in the excitation wavelength and/or emission wavelength between first and second reporter is at least 10 nm, preferably at least 20 nm, even more preferably at least 50 nm and most preferably at least 100 nm.  
     
     
         19 . The method according to  claim 2  wherein the detection oligonucleotides comprise a linker sequence, linking the sequence of detection oligonucleotide complementary to the analyte with the first reporter.  
     
     
         20 . The method according to  claim 2  wherein the capture oligonucleotides comprise a linker sequence, linking the sequence of the capture oligonucleotide complementary to the analyte with the affinity unit or the solid support.  
     
     
         21 . The method according to  claim 1  wherein at least two different analytes are being detected by providing at least two different sets of detection probes/detection oligonucleotides and at least two different sets of capture probes/capture oligonucleotides.  
     
     
         22 . The method according to  claim 21  wherein the different sets of detection probes/detection oligonucleotides are being labeled with different reporters.  
     
     
         23 . The method according to  claim 22  wherein the reporters of one set are identical, have the same excitation wavelength and/or the same emission wavelength.  
     
     
         24 . The method according to  claim 1  wherein the image recorded at the emission wavelength of the second reporter is recorded simultaneously with the image used for detecting the detection probes/detection oligonucleotides.  
     
     
         25 . The method according to  claim 24  wherein the image recorded at the emission wavelength of the second reporter is corrected such that it spatially matches with the image used for detecting the detection probes/detection oligonucleotides, or vice versa.  
     
     
         26 . The method according to  claim 1  wherein the quenching probes/quenching oligonucleotides have a quenching unit, said quenching unit preferably being a dye.  
     
     
         27 . The method according to  claim 1  wherein the first reporter is a donor of a Förster resonance energy transfer (FRET) donor-acceptor-pair and the quenching unit is an acceptor of said donor-acceptor-pair.  
     
     
         28 . The method according to  claim 26  wherein the quenching unit is a dark quencher which quenches at least partially the emission of the first reporter by dissipating an energy of an excited state of the first reporter into the environment.  
     
     
         29 . The method according to  claim 1  comprising the step of quantifying the analyte.  
     
     
         30 . The method according to  claim 29  wherein the quantification is performed by determining an amount of detection probes/detection oligonucleotides bound to the analyte.  
     
     
         31 . The method according to  claim 30  wherein the amount of detection probes/detection oligonucleotides bound to the analyte is expressed as the emission intensity emitted by the first reporter.  
     
     
         32 . The method according to  claim 30  comprising the step of determining an intensity of a background emission in the vicinity of the solid support and considering such intensity when determining the amount of detection probes/detection oligonucleotides.  
     
     
         33 . The method according to  claim 1  wherein the image of the sample used for detecting the detection probes/detection oligonucleotides is acquired at the emission wavelength of the first reporter.  
     
     
         34 . The method according to  claim 1  wherein the detection probes are aptameres, oligonucleotides, or antibodies.  
     
     
         35 . The method according to  claim 1  wherein the analyte is a protein or a nucleic acid.  
     
     
         36 . The method according to  claim 1  wherein the sample is a cell lysate, in particular a crude cell lysate, or an in vitro prepared sample.  
     
     
         37 . The method according to  claim 21  wherein the capture probes/capture oligonucleotides of different sets are attached or capable of binding to different solid supports.  
     
     
         38 . The method according to  claim 37  wherein the solid supports differ in the affinity units attached thereto, which affinity units interact with affinity units of the capture probes/capture oligonucleotides.  
     
     
         39 . The method according to  claim 1  comprising adding a potentially pharmaceutically active substance or a known drug to a cellular sample and analyzing whether such substance induces, inhibits or otherwise modulates the generation of the analyte.  
     
     
         40 . Use of the method according  claim 1  in screening for potentially pharmaceutically active substances, in diagnostics, or in determining any potential side effects of drugs.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.